D
Donald E. Goodkin
Researcher at University of California, San Francisco
Publications - 97
Citations - 18737
Donald E. Goodkin is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Multiple sclerosis & Interferon beta-1a. The author has an hindex of 51, co-authored 97 publications receiving 18226 citations. Previous affiliations of Donald E. Goodkin include University of California, Berkeley & Cleveland Clinic.
Papers
More filters
Journal ArticleDOI
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
W. Ian McDonald,A Compston,Gilles Edan,Donald E. Goodkin,Hans-Peter Hartung,Fred D. Lublin,Henry F. McFarland,Donald W. Paty,Chris H. Polman,Stephen C. Reingold,Magnhild Sandberg-Wollheim,William A. Sibley,Alan J. Thompson,Stanley van den Noort,Brian Y. Weinshenker,Jerry S. Wolinsky +15 more
TL;DR: The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.
Journal ArticleDOI
Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
Lawrence Jacobs,Diane Cookfair,Richard A. Rudick,Robert M. Herndon,John R. Richert,Andres M. Salazar,J. S. Fischer,Donald E. Goodkin,Carl V. Granger,Jack H. Simon,John J. Alam,David M. Bartoszak,Dennis Bourdette,Jonathan Braiman,Carol M. Brownscheidle,Michael E. Coats,Stanley Cohan,David S. Dougherty,R. P. Kinkel,Michele Mass,Frederick Munschauer,Roger L. Priore,Patrick M. Pullicino,Barbara J. Scherokman,Bianca Weinstock-Guttman,Ruth H. Whitham +25 more
TL;DR: Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images.
Journal ArticleDOI
A complete genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex
Jonathan L. Haines,M. Ter-minassian,A. Bazyk,James F. Gusella,Kim Dj,Henry Terwedow,Margaret A. Pericak-Vance,Rimmler Jb,C. S. Haynes,Allen D. Roses,Arthur Lee,Shaner B,Menold M,Eric Seboun,Fitoussi Rp,C. Gartioux,Reyes C,Ribierre F,Gyapay G,Jean Weissenbach,Stephen L. Hauser,Donald E. Goodkin,Robin R. Lincoln,Koichiro Usuku,Oksenberg +24 more
TL;DR: A two-stage, multi-analytical genomic screen to identify genomic regions potentially harbouring MS susceptibility genes suggested that a multifactorial aetiology, including both environmental and multiple genetic factors of moderate effect, is more likely than a simple mendelian disease gene(s).
Journal ArticleDOI
A longitudinal study of brain atrophy in relapsing multiple sclerosis
Jack H. Simon,Lawrence Jacobs,M. Campion,Richard A. Rudick,Diane Cookfair,Robert M. Herndon,John R. Richert,Andres M. Salazar,J. S. Fischer,Donald E. Goodkin,N. A. Simonian,M. Lajaunie,D. E. Miller,K. E. Wende,A. Martens-Davidson,R. P. Kinkel,Frederick Munschauer,Carol M. Brownscheidle +17 more
TL;DR: In patients with relapsing MS and only mild to moderate disability, significant cerebral atrophy is already developing that can be measured over periods of only 1 to 2 years.
Journal ArticleDOI
Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
Richard A. Rudick,N. A. Simonian,J. A. Alam,M. Campion,James Scaramucci,Wendy Jones,Michael E. Coats,Donald E. Goodkin,Bianca Weinstock-Guttman,Robert M. Herndon,Michele Mass,John R. Richert,Andres M. Salazar,Frederick Munschauer,Diane Cookfair,Jack H. Simon,Lawrence Jacobs +16 more
TL;DR: NAB directed against IFN-β have in vivo biological consequences in patients with MS and treatment decisions in MS patients treated withIFN- β should take into account development of NAB.